Last updated: August 10, 2026
Ceftazidime-avibactam, marketed in the United States as Avycaz and internationally as Zavicefta, is a hospital antibiotic used against serious infections caused by resistant Gram-negative bacteria. Its commercial value is concentrated in high-acuity hospital treatment, particularly carbapenem-resistant Enterobacterales and selected multidrug-resistant Pseudomonas aeruginosa infections.
The product has durable clinical relevance but limited revenue visibility because Pfizer does not report Avycaz or Zavicefta as standalone revenue lines. Growth depends on resistance epidemiology, hospital stewardship, diagnostic capacity, pricing, geographic access, and competition from other advanced Gram-negative antibiotics.
What is the market position of ceftazidime-avibactam?
Ceftazidime-avibactam combines the established cephalosporin ceftazidime with avibactam, a non-beta-lactam beta-lactamase inhibitor. Avibactam inhibits class A beta-lactamases, including KPC enzymes, and some class D OXA-48-like enzymes. It does not reliably inhibit metallo-beta-lactamases such as NDM, VIM, or IMP.
| Product |
Company |
Principal U.S. indications |
Initial U.S. approval |
| Avycaz |
Pfizer |
Complicated intra-abdominal infection, complicated urinary tract infection, hospital-acquired and ventilator-associated bacterial pneumonia |
2015 |
| Zavicefta |
Pfizer |
Similar serious Gram-negative infections in markets outside the United States |
2016 European authorization |
| Vabomere |
Melinta |
Complicated urinary tract infection and other serious infections caused by susceptible organisms |
2017 |
| Zerbaxa |
Merck |
Complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired and ventilator-associated bacterial pneumonia |
2014 |
| Fetroja |
Shionogi |
Complicated urinary tract infection, hospital-acquired and ventilator-associated bacterial pneumonia |
2019 |
| Emblaveo |
Pfizer and AbbVie |
Selected infections caused by aerobic Gram-negative bacteria, including organisms with limited treatment options |
2024 |
Avycaz is differentiated by activity against many KPC-producing organisms and by clinical familiarity among infectious-disease specialists. Its principal limitation is resistance caused by metallo-beta-lactamases and certain porin or efflux changes in Pseudomonas aeruginosa.
How large is the ceftazidime-avibactam market?
No authoritative public source provides a consolidated global revenue figure for ceftazidime-avibactam. Pfizer reports the product within broader commercial and hospital portfolios rather than as a separate line item in its annual financial statements.
The addressable market is defined by resistant hospital infections rather than total antibiotic prescriptions. Key demand segments are:
- Carbapenem-resistant Enterobacterales, especially KPC-producing Klebsiella pneumoniae and Escherichia coli.
- OXA-48-like Enterobacterales, particularly in Europe, the Middle East, North Africa, and parts of Asia.
- Complicated urinary tract infections requiring intravenous therapy.
- Hospital-acquired and ventilator-associated bacterial pneumonia.
- Salvage treatment for difficult-to-treat resistant Pseudomonas aeruginosa, subject to susceptibility testing.
- Combination treatment strategies for infections involving metallo-beta-lactamase-producing organisms.
The market is structurally favorable for premium pricing because treatment alternatives are limited and infections are associated with prolonged hospitalization, intensive-care utilization, and high mortality. Volume is constrained by antimicrobial stewardship. Hospitals generally reserve Avycaz for documented or strongly suspected resistant pathogens rather than routine empiric use.
What is the financial trajectory of Avycaz and Zavicefta?
The financial trajectory is likely characterized by moderate underlying demand growth with limited public disclosure of absolute revenue.
Revenue drivers
The main positive drivers are:
- Rising incidence of carbapenem-resistant Enterobacterales.
- Increased microbiological testing and resistance surveillance.
- Broader hospital adoption of rapid molecular diagnostics.
- Expansion of treatment guidelines favoring newer beta-lactam/beta-lactamase inhibitor combinations.
- Continued use in regions where KPC and OXA-48-like enzymes are prevalent.
- Pediatric label expansion and additional hospital infection use.
The main constraints are:
- Restricted hospital formularies.
- Short treatment courses compared with chronic medicines.
- Hospital procurement pressure.
- Generic competition after patent expiry.
- Resistance emerging during therapy.
- Limited activity against metallo-beta-lactamase producers.
- Competition from cefiderocol, ceftolozane-tazobactam, meropenem-vaborbactam, and ceftazidime-avibactam plus aztreonam combinations.
Pfizer’s acquisition of Hospira in 2015 transferred Avycaz into Pfizer’s portfolio shortly after approval. The deal provided Pfizer with a hospital injectable platform, manufacturing infrastructure, and a marketed anti-infective product. Pfizer does not separately disclose Avycaz revenue in its principal product tables, preventing a reliable product-level sales trend from public filings. Pfizer’s 2023 and 2024 reports identify broad product categories and selected major brands, but Avycaz is not presented as a separately quantified global franchise (Pfizer, 2024a, 2025).
When does ceftazidime-avibactam lose exclusivity?
U.S. regulatory exclusivity and patent exclusivity are different.
Avycaz received five-year new chemical entity exclusivity based on avibactam, the novel active component. Because the product was approved in 2015, that regulatory exclusivity period expired in 2020, subject to the effect of any applicable pediatric exclusivity. Regulatory exclusivity expiration did not automatically permit immediate generic launch because patent rights and FDA approval requirements remained separate barriers.
The relevant commercial risk is therefore patent expiry and the timing of abbreviated new drug applications, not NCE exclusivity alone.
U.S. exclusivity timeline
| Event |
Date or status |
| FDA approval of Avycaz |
February 25, 2015 |
| Five-year NCE exclusivity |
Expired in 2020 |
| FDA approval for hospital-acquired and ventilator-associated bacterial pneumonia |
February 1, 2018 |
| Pediatric use expansion |
Subsequently expanded under updated labeling |
| Current commercial protection |
Dependent primarily on listed patents, regulatory review, manufacturing capability, and litigation |
| Generic entry |
No publicly established broad U.S. launch date |
The FDA Orange Book is the controlling source for current listed patents, pediatric exclusivity, and patent certifications. Patent status can change through delisting, litigation, terminal disclaimers, patent-term adjustment, or settlement.
What patents protect Avycaz?
Avycaz protection is expected to include patent claims directed to avibactam, beta-lactamase-inhibitor compositions, ceftazidime-avibactam combinations, pharmaceutical formulations, dosing regimens, and manufacturing or crystallization processes.
The patent estate is more valuable when claims cover the combination product and practical intravenous formulations rather than only the active ingredient. A generic applicant may challenge one or more listed patents through a Paragraph IV certification while still seeking approval for non-infringing labeling.
The most important patent categories are:
| Patent category |
Commercial relevance |
| Avibactam composition patents |
Protect the active inhibitor and core chemical matter |
| Ceftazidime-avibactam combination patents |
Protect the marketed combination |
| Formulation patents |
Address injectable composition, stability, concentration, or reconstitution |
| Method-of-use patents |
Cover treatment of resistant bacterial infections or specific indications |
| Manufacturing patents |
Can raise process-infringement and supply-chain risk |
| Crystalline-form or salt patents |
May affect commercial API production and generic substitution |
A precise patent-expiration analysis must rely on the current FDA Orange Book record and the underlying USPTO patent files. Expiration may differ by patent because of patent-term adjustment, terminal disclaimers, pediatric extension, or patent-term restoration. The original ceftazidime patents do not provide meaningful exclusivity because ceftazidime is an older off-patent antibiotic. Avibactam and the combination are the principal sources of intellectual-property value.
Have generic companies filed Paragraph IV challenges?
Publicly visible generic competition has not produced a broadly established U.S. Avycaz launch comparable to older ceftazidime products. The absence of a major commercial generic launch does not eliminate Paragraph IV risk. An ANDA applicant can challenge Orange Book patents before market entry, and litigation may remain confidential until a complaint is filed or the FDA publishes relevant approval information.
The commercial launch threshold is high because a generic manufacturer would need:
- A compliant sterile injectable product.
- Reliable access to ceftazidime and avibactam active ingredients.
- Demonstrated pharmaceutical equivalence.
- Validated stability and reconstitution data.
- Hospital distribution and contracting capability.
- A strategy for patent litigation or settlement.
- Sufficient demand to support a high-complexity injectable product.
Generic entry would likely begin with limited hospital contracting rather than an immediate nationwide substitution. The product’s use in restricted formularies may reduce volume but support premium pricing for an approved generic.
What is the FDA regulatory status of Avycaz?
The FDA approved Avycaz in 2015 for adults with complicated intra-abdominal infections, in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis. The label was expanded in 2018 to include hospital-acquired and ventilator-associated bacterial pneumonia. Pediatric labeling was later expanded for patients three months and older for specified complicated intra-abdominal and urinary tract infections.
| FDA milestone |
Regulatory significance |
| 2015 initial approval |
Established Avycaz as a U.S. treatment for selected resistant Gram-negative infections |
| 2018 pneumonia approval |
Expanded the addressable hospital market and increased use in intensive-care settings |
| Pediatric expansion |
Improved label breadth and reduced off-label reliance |
| Current labeling |
Requires attention to renal function, dose adjustment, and susceptibility |
Renal-dose adjustment is commercially important because patients with severe infection often have changing kidney function. Dosing errors can reduce efficacy or increase toxicity, making hospital protocols and pharmacy support relevant to adoption.
How does Avycaz compare with competing resistant-infection antibiotics?
| Product |
Main strength |
Main limitation |
| Avycaz |
KPC and selected OXA-48-like Enterobacterales; established hospital use |
Limited activity against metallo-beta-lactamases |
| Vabomere |
KPC-producing Enterobacterales |
Less useful against OXA-48-like organisms and metallo-beta-lactamases |
| Zerbaxa |
Difficult-to-treat Pseudomonas and selected Gram-negative infections |
Weaker positioning against some carbapenemase-producing Enterobacterales |
| Fetroja |
Activity against some highly resistant Gram-negative pathogens, including certain metallo-beta-lactamase contexts |
Resistance and clinical-positioning complexity |
| Cefepime-enmetazobactam |
Extended-spectrum beta-lactamase-producing Enterobacterales |
Narrower strategic differentiation in some carbapenemase settings |
| Ceftazidime-avibactam plus aztreonam |
Potential activity against metallo-beta-lactamase-producing organisms |
Combination administration, clinical complexity, and higher treatment burden |
The competitive landscape is segmented by resistance mechanism. Avycaz is strongest where KPC or OXA-48-like enzymes predominate. It is less defensible in markets dominated by NDM or other metallo-beta-lactamases.
What generic launch scenarios exist?
Scenario 1: Delayed entry
A generic applicant challenges listed patents, enters litigation, and delays launch until settlement, judgment, or patent expiry. This scenario preserves Pfizer pricing and maintains hospital familiarity.
Scenario 2: At-risk launch
A generic launches before final resolution of patent litigation. This can create rapid price erosion but exposes the entrant to damages and injunctive risk.
Scenario 3: Authorized or settlement-based entry
Pfizer and a generic company agree to a later entry date or licensed launch. Entry may be limited by formulation, manufacturer, or labeling terms.
Scenario 4: Limited regional competition
A generic obtains approval but lacks sterile manufacturing scale or hospital contracts. Price pressure remains limited despite formal approval.
For Pfizer, the highest-value protection is likely the combined effect of patent claims, manufacturing know-how, regulatory complexity, and hospital relationships. For generic companies, the principal risks are patent scope, sterile injectable manufacturing, API supply, and relatively narrow clinical demand.
What licensing deals affect the product?
Avibactam originated from research associated with Novexel, which was acquired by AstraZeneca in 2010. AstraZeneca partnered with Forest Laboratories on ceftazidime-avibactam development. Actavis acquired Forest in 2014, and Pfizer acquired Hospira in 2015. These transactions explain the product’s development and commercial chain.
Pfizer later partnered with AbbVie on Emblaveo, a different fixed-dose beta-lactam/beta-lactamase inhibitor product based on aztreonam and avibactam. Emblaveo competes in the same resistant Gram-negative market but does not replace Avycaz because its microbiological positioning is different.
What is the geographic coverage and manufacturing risk?
Avycaz is marketed in the United States, while Zavicefta is marketed in multiple international jurisdictions. Geographic demand is uneven:
- The United States has high willingness to pay but strict stewardship and hospital budget controls.
- Europe has substantial OXA-48-like resistance and centralized or regional procurement.
- Latin America, the Middle East, and parts of Asia have growing resistance but greater reimbursement and access constraints.
- Markets with high NDM prevalence may favor alternative or combination regimens.
Manufacturing is a material barrier. Avycaz is an intravenous sterile product requiring validated aseptic production, compatible packaging, stability testing, and controlled reconstitution. API quality and supply continuity are important because avibactam is the differentiated component and may have fewer qualified suppliers than ceftazidime.
How strong is the Avycaz patent estate?
The estate is commercially meaningful but not immune to challenge. Strength is supported by the product’s differentiated active inhibitor, combination-specific development, sterile formulation requirements, and clinical use in serious infections. Weaknesses include the age of the original approval, expiry of NCE exclusivity, the possibility of narrow formulation claims, and the ability of generic applicants to design around method-of-use or process patents.
The likely value profile is:
| Factor |
Assessment |
| Clinical differentiation |
Strong in KPC and selected OXA-48-like infections |
| Regulatory exclusivity |
Expired |
| Patent leverage |
Potentially meaningful, dependent on current Orange Book claims |
| Generic manufacturing difficulty |
High |
| Resistance durability |
Mixed; strong by enzyme class, limited against metallo-beta-lactamases |
| Revenue transparency |
Low because Pfizer does not separately report sales |
| Long-term pricing |
Vulnerable to injectable generic entry but supported by restricted hospital use |
Key Takeaways
- Avycaz and Zavicefta are premium hospital antibiotics for resistant Gram-negative infections.
- Avibactam, rather than ceftazidime, provides the principal innovation and commercial value.
- Pfizer does not publicly report standalone global revenue for the product, so precise product-level financial forecasts cannot be derived from company filings.
- U.S. NCE exclusivity expired around 2020; remaining protection depends mainly on patents, regulatory barriers, manufacturing complexity, and litigation outcomes.
- The product is strongest against KPC and selected OXA-48-like organisms and weaker against metallo-beta-lactamase producers.
- Generic entry risk is real but may be delayed by sterile manufacturing requirements, patent litigation, hospital contracting, and limited treatment volume.
- Emblaveo, cefiderocol, meropenem-vaborbactam, ceftolozane-tazobactam, and other advanced agents create competitive pressure.
- Resistance epidemiology and diagnostic testing are the central market-growth variables.
FAQs
What is the active ingredient in Avycaz?
Avycaz contains ceftazidime and avibactam sodium. Ceftazidime is the antibacterial cephalosporin; avibactam inhibits selected beta-lactamase enzymes.
Is ceftazidime-avibactam a biologic or a generic drug?
It is a conventional small-molecule injectable drug, not a biologic. Ceftazidime is off patent as an older antibiotic, while avibactam and the combination created the principal product-specific protection.
Does Avycaz treat NDM-producing bacteria?
Avycaz alone generally does not provide reliable activity against NDM-producing organisms. Combination treatment with aztreonam may be considered in certain clinical settings under specialist guidance.
Which company owns Avycaz?
Pfizer commercializes Avycaz in the United States and Zavicefta in international markets. The product entered Pfizer’s portfolio through the Hospira acquisition.
Is Avycaz likely to face price erosion after generic entry?
Yes. Sterile injectable manufacturing and hospital procurement may moderate the speed of erosion, but a fully substitutable generic would likely reduce price and contract share over time.
References
-
European Medicines Agency. (2016). Zavicefta: EPAR product information. https://www.ema.europa.eu/
-
Food and Drug Administration. (2015). FDA approves Avycaz to treat complicated intra-abdominal and urinary tract infections. https://www.fda.gov/
-
Food and Drug Administration. (2018). FDA approves Avycaz for hospital-acquired and ventilator-associated bacterial pneumonia. https://www.fda.gov/
-
Food and Drug Administration. (2024). Avycaz prescribing information. Pfizer Inc. https://labeling.pfizer.com/
-
Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Infectious Diseases Society of America. (2024). IDSA guidance on the treatment of antimicrobial-resistant Gram-negative infections. https://www.idsociety.org/
-
Pfizer Inc. (2024a). 2023 annual report. https://www.pfizer.com/investor
-
Pfizer Inc. (2025). 2024 annual report. https://www.pfizer.com/investor
